Plant extracts of the European mistletoe (MTE), Viscum album, the most widely used cancer treatment in Germany, have been used in European countries as sole intervention or as adjunct to conventional cancer therapies for more than 80 years. Preclinical data suggest immunostimulatory and cytotoxic effects of MTE. While the clinical efficacy of MTE in cancer is being investigated, toxicity and potential interactions of MTE with standard chemotherapeutic agents are unknown. Gemcitabine is an approved antimetabolite chemotherapeutic agent effective as single agent in patients with solid tumors (ST). The documented metabolism and pharmacokinetics of gemcitabine make this agent well suited for the study of botanical-chemotherapy drug interactions (BDIA) in cancer. Based on reports of altered drug metabolism associated with botanical preparations, research into BDIA has intensified. The phase I, 2-stage, dose-escalation study outlined here will test MTE with gemcitabine as a paradigm for the phase I investigation of botanical-drug combination treatments in patients with advanced ST. The protocol including the following components has been reviewed and approved by the National Cancer Institute Institutional Review Board (IRB), the National Naval Medical Center IRB, and the Navy Clinical Investigation Program (study 02-074): (1) use of a standardized MTE, approved by the Food and Drug Administration for investigational use; (2) independent verification of key MTE components considered biologically active; (3) identification of contaminants and adulterants; (4) pharmacokinetics of gemcitabine and its principal metabolites before and upon exposure to MTE; (5) safety and toxicity data collection; (6) assays of plasma ML antibody production in vivo; and (7) pharmacodynamic studies of the botanical-drug combination.
The tree parasitic plant mistletoe (Viscum album L.
[Viscaceae]) has been in use as a cultic or medicinal plant for several thousand years. In the modern era, it was first introduced by Rudolf Steiner as a plant extract preparation for the treatment of malignant diseases. 1 The National Cancer Institute (http:// cancernet.nci. nih.gov/cam/mistletoe.htm) recently concluded that animal studies investigating the ability of mistletoe extracts to slow tumor growth have produced mixed results. Moreover, the review stated that to date, there is no conclusive evidence from randomized clinical trials suggesting that mistletoe or any of its components are effective treatments for patients with cancer. Recent reviews in the European literature have come to similar conclusions. [2] [3] [4] However, this view is not reflected in clinical practice, as indicated by the great popularity of mistletoe preparations in clinical cancer treatment in several European countries. 5
Effects of Mistletoe on the Immune System
A number of studies have reported immunostimulatory effects of mistletoe extracts on mononuclear cells, 6 lymphocytes, 7-9 macrophages, 10 and natural killer (NK) cells. 11, 12 Mistletoe extracts contain a number of components considered biologically active, including mistletoe lectins and viscotoxins. The biologic effects of mistletoe lectins have been studied most extensively. 13, 14 In vitro studies of purified mistletoe lectins (ML-I to III) have demonstrated both cytotoxic and immunostimulatory effects. [15] [16] [17] [18] [19] [20] Mistletoe and Cytokines Mistletoe lectins have been shown to stimulate secretion of a number of cytokines. TNF-α and IL-1, and to a variable degree IL-6, were stimulated by mistletoe lectins in cultured mononuclear cells of healthy volunteers. 21 ML-I may enhance cytotoxic NK-cell activity by augmentation of IL-12 secretion. 22 Purified ML-I was shown to increase secretion of TNF-α, IL-1, and IL-6 in vitro from PMNC derived from patient samples. Single-dose ML-1 injection increased secretion of TNF-α and IL-6 over 1 to 3 hours in 8 breast cancer patients. 23 Incubation of tumor cells with mistletoe lectins resulted in enhanced TNF-α-induced apoptosis 24 and induction of FAS ligand. 25 The cytokines IL-6, IL-12, TNF-α, and IFN-γ have served as parameters of the immunostimulatory effect of mistletoe on PMNC and NK cells in vitro.
Mistletoe and Neutrophils
Preclinical data suggest that mistletoe extract reduces leukopenia in mice after treatment with radiation and cyclophosphamide 26 and stimulates neutropoiesis in mice after cyclophosphamide chemotherapy 27 and in blood of breast cancer patients. 12 ML-1 has recently been shown to up regulate protein synthesis in neutrophils in a dose-dependent fashion at low doses, while high doses resulted in neutrophil apoptosis via a caspase-dependent mechanism. 28
Mistletoe Lectin Antibodies
The formation of antibodies directed against mistletoe lectins has been documented in several research studies. Twenty-three cancer patients treated with incremental doses of mistletoe Helixor™ for 2 months to 6 years were evaluated. 29 Antibodies against mistletoe lectin and other unspecified components of the extract were detected by enzyme linked immunosorbent assay (ELISA), immune diffusion, and Western blot. Antibody titers correlated with the duration of therapy and size of dose. The antibodies were of the IgG type and mainly belonged to subclasses IgG 1 , IgG 2 , and IgG 4 . Only 4 of the 23 patients produced IgG 3 antibodies. IgA antibodies were also detected in 9 patients. No IgM or IgE antibodies were detected. An IgG fraction obtained from the pooled sera of patients neutralized the inhibitory effect of mistletoe lectin on mitogen-induced lymphocyte proliferation. These data suggest that in vivo antibody formation has a protective effect against the toxicity of mistletoe lectins to normal somatic cells.
Another study of 34 patients who developed proven adverse effects to mistletoe extract (Helixor™) demonstrated the formation of ML-1 antibodies of the IgE type, consistent with an injection site phenomenon, which were not present in patients without adverse effects. 30 The clinical relevance of these findings is unknown and has not been evaluated in a controlled clinical investigation, but a possible role of ML antibodies in the neutralization of mistletoe lectin activity in vivo has been debated. 29, 31 There are several possible mechanisms by which lectin antibodies might modify mistletoe effects in patients on gemcitabine and mistletoe. High lectin antibody plasma levels may result in increased gemcitabine toxicity and decrease of parameters of immune function. However, reduced toxicity of mistletoe on normal cells in patients with detectable ML antibodies could also translate into a reduced mistletoe-specific toxicity profile in patients with ML antibody formation.
Clinical Experience With Mistletoe Extracts in Cancer Patients
The mistletoe preparation, Iscador™, is the most commonly used oncological medicine in Germany. 5 Several reviews [2] [3] [4] have reported inconclusive results regarding tumor response and survival prolongation on treatment with a number of mistletoe preparations, based on lack of rigor of design and inconsistency in study design and data reporting. Several recently published studies confirm this mixed picture. A randomized study was conducted in which 38 patients with primary central nervous system gliomas were treated with galactoside-specific mistletoe lectin-1 (ML-1) standardized mistletoe extract (Eurixor™) versus placebo. Prolonged disease-free and overall survival was evident only in the subgroup of mistletoe-treated patients with stage III-IV disease. Nine patients were excluded from analysis due to lack of study compliance. 32 A randomized controlled trial of adjuvant ML-1 standardized mistletoe extract (Eurixor) in 477 patients with head and neck cancer failed to show survival or quality of life (QOL) benefits for the mistletoe group. 33 However, almost 100 patients less than projected were recruited, 15% of the patients in the mistletoe group did not complete the prescribed regimen, and the ML-1 content of the preparation used was low, which has led to dispute over the study results. 5 A prospective randomized 4-arm investigation of 830 patients with melanoma compared low-dose recombinant IFNα2b, recombinant IFNγ, a mistletoe extract (Iscador), and an observational control. A mistletoe arm was added to the originally planned 3-arm study as a fourth arm after a study-design modification. Mistletoe treatment did not show any clinical benefit, and node-positive patients on mistletoe had a higher incidence of brain metastasis associated with decreased overall survival than patients in the other study arms, although the results did not reach statistical significance. Study data at this point have not been reported in full, despite study completion in 1996, allowing for only limited evaluation of the value of the study. 34 Mistletoe treatment (Eurixor preparation) of patients with stage III-IV breast cancer resulted in improved QOL assessed by unspecified questionnaire associated with increased β-endorphin release and preservation of cellular immune function on adjuvant chemotherapy, suggesting involvement of the neuroendocrine-immune axis in the generation of mistletoe effects. 35, 36 Mistletoe (Eurixor) resulted in transient disease and QOL stabilization for 8 weeks in a study of 15 patients with advanced pancreatic cancer, but no clinical tumor responses were observed. 37 Recently, Grossharth-Maticek et al reported on the survival of patients treated with mistletoe extract (Iscador preparation) as participants of a large, epidemiological study of the influence of psychosomatic self-regulation on cancer survival. 5 A final cohort of 396 matched pairs of patients was followed prospectively since 1988 with final follow-up and data analysis in 1998. Forty percent of the matched pairs had colorectal cancer, and 30% had breast cancer. A subgroup of 112 pairs underwent randomization to Iscador versus control treatment. A positive correlation between level of self-control as assessed by previously established measures and longer survival on Iscador treatment was found. Results from the study of the randomized subgroup confirmed these findings. However, the outcome variables of survival on Iscador and an increased level of self-control appeared interdependent.
Anecdotal reports and experience in clinical practice suggest that mistletoe extract appears to be well tolerated. However, limited toxicity data based on controlled clinical trials are available. In a phase I study in HIV-positive patients, limited toxicities included flulike symptoms, gingivitis, eosinophilia, and a slight rise in serum urea and creatinine. No maximum tolerated dose (MTD) was reached over a dose range of 0.01 to 10 mg daily of V. album Quercus Frischsaft (QuFrF). 38
Botanical-Drug Interactions
Interactions between botanicals and widely used therapeutic agents have recently become a focus of increased awareness and scrutiny due to potential toxicity, safety, and efficacy concerns related to increased use of complementary and alternative medi-cine (CAM) practices. A number of herbs (ginko, garlic, dong quai, danshen, St John's wort) interact with the metabolism or activity of warfarin, serotoninreuptake inhibitors, antiretrovirals, digoxin, theophylline, cyclosporin, and phenprocoumon; others interfere with the metabolism of antidepressants (Panax ginseng), neuroleptic drugs (betel nut), corticosteroids (liquorice), and phenytoin (shankapushpi) (78-85). According to a recent systematic review, 39 5 other of the 7 top-selling herbal medicines in this country interfere with the metabolism or efficacy of approved synthetic drugs (Table 1) .
There is a paucity of literature about the interaction of herbs with chemotherapeutic agents. Recently, a report suggested that St John's wort alters hepatic metabolism of irinotecan if administered concurrently to cancer patients. 40 As a result of enhanced hepatic clearance of irinotecan based on St John's wort's induction of the hepatic p450 enzyme complex and associated reduced plasma concentrations, patients taking St John's wort could potentially be at risk for decreased survival benefit.
Botanical Product Content Verification
While the potential for drug-botanical interactions has captured public and scientific attention recently, the issue of botanical product quality and content variability needs to be addressed prior to any scientific evaluation of the safety and efficacy of any botanical product. Several recent reports have documented a considerable variability in product concentration and composition of commercially available botanical products. [41] [42] [43] [44] [45] [46] In addition, the possibility of product contamination has been of increasing concern in the treatment of cancer, particularly illustrated by the recent concerns about the Chinese herbal product PC-SPES. 47, 48 To address issues of quality control regarding content and contamination, a mistletoe product was chosen that meets a high standard of quality:
1. produced by a well-known manufacturer in mistletoe products with long-standing experience and established quality control/product analysis certification process and In addition, the product was subjected to content verification analysis by an independent laboratory with expertise in botanical product analysis, where a number of verification analyses were performed:
1. heavy metal analysis, 2. verification of key components of extract ("fingerprint"), 3. analysis for contaminants/drugs, and 4. product stability testing at 6, 12, and 24 months after production.
With the adoption of a rigorous quality control process for the botanical used in a clinical investigation, the risk for product-related unforeseen effects on patients, as well as the potential for distortion of study outcomes, is minimized.
Study Rationale
Published reports of controlled clinical trial data on safety and toxicity of botanicals either as single agent or when administered with approved pharmacologic agents are limited, especially in oncology. The study paradigm discussed in this article is presented as a model for (1) the investigation of safety and toxicity of drug-botanical combinations in the treatment of cancer and (2) the evaluation of the potential clinical benefit of such combinations in modifying the toxicity profile of cancer chemotherapy.
The chemotherapeutic agent gemcitabine lends itself well to the study of botanical-drug combinations in cancer:
• Gemcitabine is approved by the FDA as both a single agent and in combination regimens, with documented efficacy for the treatment of a variety of cancers, including colorectal, breast, lung, and pancreactic cancer in addition to genitourinary cancers. [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] • The toxicity and safety profile is well established.
• Gemcitabine plasma pharmacokinetics and metabolism in humans have been well characterized. 49, 50, [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] Preclinical and clinical data available on mistletoe extracts provide several characteristics that call for further investigation of this botanical in cancer treatment:
• A substantial body of preclinical and some clinical data suggest immunostimulatory effects of mistletoe extracts with tumor-reducing potential.
• Controlled clinical safety/toxicity data as a single agent as well as in combination treatment in cancer patients have not been well characterized.
• Some clinical trial evidence suggests improvement in QOL with mistletoe in cancer patients.
• Survival benefit claims with mistletoe treatment have been based largely on anecdotal reports and inconsistent data from clinical trials of varying quality. • There is widespread use of mistletoe in clinical practice in Europe.
In addition to the safety and toxicity studies, we are planning correlative studies to shed light on possible mechanistic aspects of drug-botanical interaction and to broaden the understanding of potentially beneficial systemic effects elicited in cancer patients by adding the botanical agent to a standard chemotherapy.
Study Hypotheses
Based on the information above, we raised several questions to be answered in the study:
1. How safe is mistletoe when given with gemcitabine to patients with advanced solid tumors? 2. Is there a defined tolerated dosing range for the combination? 3. Does mistletoe affect gemcitabine metabolism? 4. Is there evidence for immunostimulatory effects of mistletoe when given with gemcitabine?
A set of hypotheses was developed to address these questions:
1. Mistletoe does not affect gemcitabine pharmacokinetics. 2. The addition of mistletoe extract improves the gemcitabine safety and toxicity profile. 3. Mistletoe extract results in stimulation of cellular and humoral immunity. 4. The level of mistletoe lectin antibody formation predicts the toxicity profile of gemcitabine.
Study Objectives
The study objectives are outlined in Table 2 . Two broad categories of objectives were developed.
Safety and toxicity. In addition to establishing the safety and toxicity profile and the MTD of the mistletoegemcitabine combination, detailed pharmacokinetic studies of gemcitabine and its metabolites will determine the possibility of botanical-drug interactions resulting in altered gemcitabine metabolism.
Botanical/drug pharmacodynamics. A series of correlative studies will investigate the ability of mistletoe extract to stimulate granulocyte proliferation and cellular immunity in patients receiving gemcitabine chemotherapy. In addition, gene expression profiling by cDNA microarray with a particular focus on cytokine, cytokine receptor, and apoptotic pathway genes will follow up on available in vitro data to explore the in vivo effects of mistletoe extracts on cancer patients receiving gemcitabine chemotherapy. Plasma mistletoe lectin MoAb (ML-MoAb) formation studies will investigate the host response to mistletoe extract. Immunologic outcome parameters as well as toxicity data will be correlated with ML-MoAb plasma level data to evaluate the effect of ML-MoAb formation on the clinical safety and toxicity profile of the botanicaldrug combination and investigate correlations between the MoAb plasma concentration and the level of immunostimulation in individual patients.
Study Design

Two-Stage Design
A study design was chosen that would allow for a rigorous evaluation of the toxicity and safety as well as parameters of drug metabolism of a botanical-drug combination. For this purpose, a phase I study design was developed that would allow for dose-dependent evaluation of each of the study regimen components. As outlined in Figure 1 , the study is composed of 2 stages. In each stage, cohorts of 3 patients will be recruited per dose level in a 2-phase dose-escalation schema. During stage I, the dose of mistletoe extract administered will be escalated in groups of 3 patients through a series of 5 target dose levels ranging from 20 to 250 mg per dose (Table 3 ) using a fixed gemcitabine dose of 750 mg/m 2 . Once an MTD for mistletoe has been reached in stage I, the mistletoe dose level immediately below the MTD will be used as the fixed mistletoe dose for stage II.
Stage II of the study (Table 4 ) constitutes a doseescalation scheme for gemcitabine from a starting dose of 900 mg/m 2 with 20% dose increments per dose level until the MTD is reached. Based on published gemcitabine phase I study data, 49 ,50,65-74 6 dose levels are anticipated, with a maximum gemcitabine dose of 2246 mg/m 2 . The MTD reached during stage II will be considered the MTD for the combination of mistletoe extract plus gemcitabine. Table 5 outlines the study regimen. Gemcitabine is administered on day 1 and day 8 of a 21-day cycle (2 out of 3 weeks) as a 30-minute intravenous infusion. This weekly regimen, as contrasted with more frequent dosing schedules in prior studies, has been shown to reduce the risk for toxicity. Mistletoe extract is given per manufacturer specifications (www.helixor.de), as well as based on clinical use, via subcutaneous injection daily starting on day 8 after initiation of the study regimen.
Study Regimen
The duration of the study regimen is 3 cycles or 9 weeks. Restaging studies will be performed at the conclusion of the study regimen, or earlier as clinically indicated, to assess clinical benefit of the study 
Outcome Measures Primary Outcome Measures
Safety and Toxicity of Mistletoe-Gemcitabine Combination Safety and toxicity data will be closely monitored and recorded on all patients. Toxicities will be graded according to the current Common Toxicity Criteria (CTCAE v3.0, http://ctep.info.nih.gov/reporting/ ctc.html).
Pharmacokinetic Studies of Gemcitabine
Pharmacokinetics studies will be performed on patient blood samples at baseline prior to initiation of the study regimen and after the first dose of gemcitabine without mistletoe (C1D1) and subsequently after patients have received 3 cycles of gemcitabine and reached mistletoe target dose (C3D8).
Secondary Outcome Measures
Modification of Chemotherapy Toxicity by Mistletoe
Time to neutrophil count recovery. As discussed above, preliminary results suggest that administration of mistletoe extract to cancer patients may hasten neutrophil count recovery after administration of cytotoxic chemotherapy. This hypothesis will be tested by measuring the time to neutrophil count recovery after administration of gemcitabine alone as well as while being exposed to mistletoe extract. In addition, these data will be correlated with available pharmacokin-etic results of gemcitabine metabolism and historical incidence data on hematologic toxicities after gemcitabine.
Mistletoe as an Immunomodulator
Plasma cytokine levels. Plasma cytokine levels will be measured at baseline and while exposed to both gemcitabine and mistletoe at target dose level. In addition, comparison analyses of cytokine levels in patients in relation to the dose of mistletoe and gemcitabine will be performed within each stage of the study as well as between stages. The hypothesis will be tested that increasing doses of mistletoe will increase stimulation of cytokine release. The possibility of interference of increasing doses of gemcitabine with this effect will also be explored.
Cytokine/apoptotic pathway gene expression profiling. In parallel with plasma level determination, cytokine stimulation will also be tested at the transcriptional level by applying gene microarray techniques to cytokine and cytokine receptor genes. Based on preliminary preclinical data, the activation of genes involved in apoptotic pathways will also be studied. These results will be correlated with the plasma cytokine assay results to explore the possibility of differential effects of mistletoe at the transcriptional and translational level.
Host Response to Mistletoe ML1/3 MoAb ELISA assay. There is ongoing debate as to the functional impact of mistletoe lectin antibody formation on treatment toxicity and efficacy. In this study, we will endeavor to determine if ML-MoAb formation is mistletoe dose-dependent, whether it affects the toxicity spectrum of the combination regimen, and determine the immunological activity of the mistletoe regimen.
Conclusion
One of the challenges in the evolving field of CAM research has been to develop novel research paradigms for the study of complex CAM interventions, such as administration of botanicals. The clinical study paradigm presented in this article was developed as a platform to understand the basic parameters of the CAM intervention and its interaction with cancer chemotherapy. The results of this investigation may allow for a better understanding of the botanical intervention as well as advance the understanding of the role and effects of complex CAM interventions in patients who undergo cancer therapy. Gemcitabine (weekly) X X X X X X Mistletoe (daily) X X X X X X X X Pharmacokinetics X X
